Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 1
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern.
García-Pérez J, Bermejo M, Ramírez-García A, De La Torre-Tarazona HE, Cascajero A, Castillo de la Osa M, Jiménez P, Aparicio Gómez M, Calonge E, Sancho-López A, Payares-Herrera C, Layunta Acero R, Vicente-Izquierdo L, Avendaño-Solá C, Alcamí J, Pérez-Olmeda M, Díez-Fuertes F. García-Pérez J, et al. Among authors: de la torre tarazona he. J Med Virol. 2023 Mar;95(3):e28679. doi: 10.1002/jmv.28679. J Med Virol. 2023. PMID: 36929737
Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study.
Ascaso-Del-Rio A, García-Pérez J, Pérez-Olmeda M, Arana-Arri E, Vergara I, Pérez-Ingidua C, Bermejo M, Castillo de la Osa M, Imaz-Ayo N, Riaño Fernández I, Astasio González O, Díez-Fuertes F, Meijide S, Arrizabalaga J, Hernández Gutiérrez L, de la Torre-Tarazona HE, Mariano Lázaro A, Vargas-Castrillón E, Alcamí J, Portolés A; RescueVac study Group. Ascaso-Del-Rio A, et al. Among authors: de la torre tarazona he. EClinicalMedicine. 2022 Jul 1;51:101542. doi: 10.1016/j.eclinm.2022.101542. eCollection 2022 Sep. EClinicalMedicine. 2022. PMID: 35795398 Free PMC article.
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.
García-Pérez J, González-Pérez M, Castillo de la Osa M, Borobia AM, Castaño L, Bertrán MJ, Campins M, Portolés A, Lora D, Bermejo M, Conde P, Hernández-Gutierrez L, Carcas A, Arana-Arri E, Tortajada M, Fuentes I, Ascaso A, García-Morales MT, Erick de la Torre-Tarazona H, Arribas JR, Imaz-Ayo N, Mellado-Pau E, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Ochando J, Belda-Iniesta C, Frías J, Alcamí J, Pérez-Olmeda M; CombiVacS study Group. García-Pérez J, et al. Among authors: erick de la torre tarazona h. EClinicalMedicine. 2022 Jul 1;50:101529. doi: 10.1016/j.eclinm.2022.101529. eCollection 2022 Aug. EClinicalMedicine. 2022. PMID: 35795713 Free PMC article.
Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients.
Ramírez de Arellano E, Díez-Fuertes F, Aguilar F, de la Torre Tarazona HE, Sánchez-Lara S, Lao Y, Vicario JL, García F, González-Garcia J, Pulido F, Gutierrez-Rodero F, Moreno S, Iribarren JA, Viciana P, Vilches C, Ramos M, Capa L, Alcamí J, Del Val M. Ramírez de Arellano E, et al. Among authors: de la torre tarazona he. PLoS One. 2019 Aug 8;14(8):e0220459. doi: 10.1371/journal.pone.0220459. eCollection 2019. PLoS One. 2019. PMID: 31393887 Free PMC article.